GHK-Cu peptide therapy is typically administered through small subcutaneous injections under the supervision of our medical providers
These clinical activities are referenced within the peer-reviewed preclinical literature rather than reported as standalone pivotal-trial publications
1 2 3 Wintrobe's Clinical Hematology Thirteenth Edition
8(2): 3916 McCabe PH, Michel NC, McNew CD, et al
2.3 Stability studies To investigate the effects of DOXHCl solution on temperature and bright light, it was placed at 40 C for the high-temperature testing and at an illumination of 4,500 lx 500 lx for photostability testing, both of which were sampled on days 0, 5 and 10 for detection of DOX by HPLC
Following subcutaneous administration in clinical models: Both components demonstrate prolonged absorption with peak plasma concentrations occurring 24-72 hours post-injection GLP3 exhibits approximately 6-day half-life enabling once-weekly dosing Cagrilintide demonstrates 120-165 hour half-life (5-7 days) suitable for weekly administration Lipid conjugation of both peptides enables albumin binding and extended systemic circulation Distribution patterns show systemic exposure with concentration in metabolically active tissues The fatty diacid modifications on both peptides (C20 for GLP3 , eicosanedioic acid for cagrilintide) serve as albumin-binding moieties that dramatically extend plasma residence time compared to native peptides
